Emerging therapies targeting the ubiquitin proteasome system in cancer

Journal of Clinical Investigation

Volumn 124, Issue 1, 2014, Pages 6-12

  Weathington, Nathaniel M ^a,b   Mallampalli, Rama K ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; LIGASE INHIBITOR; PROTEASOME INHIBITOR; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 ANTAGONIST; UNCLASSIFIED DRUG;

CANCER THERAPY; CELL FUNCTION; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; UBIQUITIN PROTEASOME SYSTEM;

EID: 84892948811     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71602     Document Type: Review

References (72)

1. Richardson PG, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-2617.
2. San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
3. Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-2520.
4. Cavo M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120(1):9-19.
5. Howlader N, et al. SEER Cancer Statistics Review (CSR) 1975-2010. National Cancer Institute Web Site. http://seer.cancer.gov/csr/1975-2010/. Updated June 14, 2013. Accessed November 15, 2013.
6. Jakubowiak AJ, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and lowdose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801-1809.
7. Elkinson S, McCormack PL. Pomalidomide: first global approval. Drugs. 2013;73(6):595-604.
8. MacGurn JA, Hsu PC, Emr SD. Ubiquitin and membrane protein turnover: from cradle to grave. Annu Rev Biochem. 2012;81:231-259.
9. Clague MJ, Liu H, Urbe S. Governance of endocytic trafficking and signaling by reversible ubiquitylation. Dev Cell. 2012;23(3):457-467.
10. Rieser E, Cordier SM, Walczak H. Linear ubiquitination: a newly discovered regulator of cell signalling. Trends Biochem Sci. 2013;38(2):94-102.
11. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol. 2004;5(3):177-187.
12. Cardozo T, Pagano M. The scf ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5(9):739-751.
13. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10(8):550-563.
14. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-173.
15. Perry WL, Hustad CM, Swing DA, O'Sullivan TN, Jenkins NA, Copeland NG. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet. 1998;18(2):143-146.
16. Lohr NJ, et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet. 2010;86(3):447-453.
17. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-|B. Nature. 2003;424(6950):797-801.
18. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-|B signalling by deubiquitination. Nature. 2003;424(6950):801-805.
19. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003;424(6950):793-796.
20. Sun SC. Cyld: a tumor suppressor deubiquitinase regulating NF-|B activation and diverse biological processes. Cell Death Differ. 2010;17:25-34.
21. Richardson PG, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120.
22. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006;14(3):451-456.
23. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034-2042.
24. Vij R, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158(6):739-748.
25. Vij R, et al. An open-label, single-arm, phase 2 (PX- 171-004) study of single-agent carfilzomib in bortezomib- naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119(24):5661-5670.
26. Hurchla MA, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 2013;27:430-440.
27. Hájek R, Bryce R, Ro S, Klencke B, Ludwig H. Design and rationale of focus (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012;12:415.
28. Chauhan D, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8(5):407-419.
29. Millward M, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30(6):2303-2317.
30. Rodler E, et al. First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. J Clin Oncol. 2010;28:15s(suppl; abstr 3071).
31. ClinicalTrials.gov. NIH Web Site. http://www. clinicaltrials.gov. Accessed November 15, 2013.
32. Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458(7239):732-736.
33. Ceccarelli DF, et al. An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell. 2011;145(7):1075-1087.
34. Khoury K, Domling A. P53 Mdm2 inhibitors. Curr Pharm Des. 2012;18(30):4668-4678.
35. Chargari C, et al. Preclinical assessment of JNJ- 26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett. 2011;312(2):209-218.
36. Vassilev LT, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848.
37. Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011; 10(1):69-79.
38. Tabernero J, et al. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6313-6321.
39. Voltan R, et al. Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts. Clin Cancer Res. 2013;19(14):3871-3880.
40. Altun M, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol. 2011;18(11):1401-1412.
41. Chauhan D, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22(3):345-358.
42. Zeng X, et al. Pharmacologic inhibition of the anaphase- promoting complex induces a spindle checkpoint- dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010;18(4):382-395.
43. Buckley DL, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1〈 interaction. J Am Chem Soc. 2012;134(10):4465-4468.
44. Aghajan M, et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat Biotechnol. 2010;28(7):738-742.
45. Orlicky S, Tang X, Neduva V, Elowe N, Brown ED, Sicheri F, Tyers M. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol. 2010;28(7):733-737.
46. Chen BB, et al. A combinatorial F box protein directed pathway controls traf adaptor stability to regulate inflammation. Nat Immunol. 2013;14(5):470-479.
47. Mallampalli RK, et al. Targeting F box protein Fbxo3 to control cytokine-driven inflammation. J Immunol. 2013;191(10):5247-5255.
48. Chen BB, Glasser JR, Coon TA, Mallampalli RK. F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest. Oncogene. 2012;31:2566-2579.
49. Chen BB, Glasser JR, Coon TA, Mallampalli RK. Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates aurora B to inhibit tumorigenesis. Cell Death Dis. 2013;4:e759.
50. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-l1 activity in the H1299 lung cancer cell line. Chem Biol. 2003;10(9):837-846.
51. Aleo E, Henderson CJ, Fontanini A, Solazzo B, Brancolini C. Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res. 2006;66(18):9235-9244.
52. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 2010;70(22):9265-9276.
53. Lee BH, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010;467(7312):179-184.
54. Shinji S, et al. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncol Rep. 2006; 15(3):539-543.
55. Wu N, Liu C, Bai C, Han YP, Cho WC, Li Q. Overexpression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of ®-catenin. Int J Mol Sci. 2013;14(6):10749- 10760.
56. D'Arcy P, et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011;17(12):1636-1640.
57. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
58. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its imid derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314-322.
59. Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008; 111(8):3968-3977.
60. Ito T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-1350.
61. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326-2335.
62. Zhu YX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771-4779.
63. Broyl A, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624-627.
64. Hiepe F, et al. Refractory SLE patients respond to the proteasome inhibitor bortezomib. Ann Rheum Dis. 2012;71:A15-A16.
65. Quartuccio L, Rupolo M, Michieli M, De Vita S. Efficacy tolerability of repeated cycles of a onceweekly regimen of bortezomib in lupus [published online ahead of print August 20, 2013]. Rheumatology (Oxford). doi:10.1093/ rheumatology/ket284.
66. van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BA, Jansen G. The proteasome inhibitor bortezomib inhibits the release of NF|B-inducible cytokines and induces apoptosis of activated t cells from rheumatoid arthritis patients. Clin Exp Rheumatol. 2009;27(1):92-98.
67. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40(2)427-446.
68. Weathington NM, Sznajder JI, Mallampalli RK. The emerging role of the ubiquitin proteasome in pulmonary biology disease. Am J Respir Crit Care Med. 2013;188(5):530-537.
69. Willis MS, Townley-Tilson WH, Kang EY, Homeister JW, Patterson C. Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circ Res. 2010;106(3):463-478.
70. Huang R, et al. The ncgc pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3(80):80ps16.
71. Sun W, et al. Rapid identification of antifungal compounds against exserohilum rostratum using high throughput drug repurposing screens. PLoS One. 2013;8(8):e70506.
72. Xia M, et al. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013;14(7):638-647.